NEOGENOMICS INC — Director's Dealing 2016

Dec 7, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2016-12-06

Reporting Person: BRODIE STEVEN G. (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-12-06	Common Stock	M	10000	$1.69	Acquired	65953	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-12-06	Stock Option (Right to Buy)	$1.69	X	10000	Disposed	2017-04-12	Common Stock (10000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$3.76	2018-04-16	Common Stock (10000)	10000	Direct
Stock Option (Right to Buy)	$3.45	2019-03-05	Common Stock (20000)	20000	Direct
Stock Option (Right to Buy)	$4.78	2020-05-04	Common Stock (120000)	120000	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (100000)	100000	Direct

Footnotes

F1: On April 12, 2012 Dr.Brodie was granted 10,000 stock options. There was immediate vesting of 2,500 shares and then 2,500 shares will vest on the next three anniversary dates of the grant date.

F2: On April 16, 2013 Dr. Brodie was granted 10,000 stock options. These options will vest ratably over the next three anniversary dates of the grant dates.

F3: On March 5, 2014 Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date.

F4: On May 4, 2015 Dr, Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.

F5: On April 20, 2016, Mr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.